Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2026)

Rani Therapeutics Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$27000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 99.28% year-over-year to -$27000.0; the TTM figure through Mar 2026 stood at $44.0 million (up 352.11% YoY), while the FY2025 annual figure was $40.3 million, up 196.65% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$27000.0, down from $44.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $44.9 million in Q4 2025, with the low at -$3.7 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is $108500.0 (2023), against an average of $5.2 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 15622.45% in 2024, then plunged 3183.47% in 2025.
• Rani Therapeutics Holdings' Cash from Financing Activities stood at $14.9 million in 2022, then sank by 99.35% to $96000.0 in 2023, then surged by 5753.12% to $5.6 million in 2024, then soared by 698.22% to $44.9 million in 2025, then sank by 100.06% to -$27000.0 in 2026.
• Business Quant data shows RANI's Cash from Financing Activities at -$27000.0 in Q1 2026, $44.9 million in Q4 2025, and -$1.0 million in Q3 2025.